FRANCO M. MUGGIA, M.D.; PETER A. CASSILETH, M.D.; MANUEL OCHOA JR., M.D.; FREDERICK A. FLATOW, M.D.; ALFRED GELLHORN, M.D., F.A.C.P.; GEORGE A. HYMAN, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Thirty-four postmenopausal women and two men disseminated breast cancer were treated with medroxyprogesterone acetate, a synthetic steroid with potent and specific progestational activity. Seven women demonstrated objective tumor regression. The mean duration of the response was 12 months. Tumor regression occurred in an additional five patients when the medroxyprogesterone acetate was combined with estrogens. A long "free interval" (from initial therapy to the appearance of distant metastases) and prior response to other hormones appeared to correlate with responsiveness to the progestogen. No serious drug toxicity was encountered.
MUGGIA FM, CASSILETH PA, OCHOA M, FLATOW FA, GELLHORN A, HYMAN GA. Treatment of Breast Cancer with Medroxyprogesterone Acetate. Ann Intern Med. ;68:328–337. doi: 10.7326/0003-4819-68-2-328
Download citation file:
Published: Ann Intern Med. 1968;68(2):328-337.
Breast Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use